Location of Repository

Liver International

By Paulo Adriano Schwingel, Helma Pinchemel Cotrim, Bernardo R. Salles, Carlos E. Almeida, Crimerio Ribeiro dos Santos Junior, Bruno Nachef, Antonio R. Andrade and Cláudio Cesar Zoppi

Abstract

texto completo: acesso restrito. p. 348-353.Background: Industrial toxin and drugs have been associated with non-alcoholic fatty liver disease (NAFLD); in these cases, the disease has been termed toxicant-associated steatohepatitis (TASH). Aim: This study hypothe-sizes that the use of anabolic-androgenic steroids (AAS) could also be a risk factor to TASH or better toxicant-associated fatty liver disease (TAFLD) development. Methodology: Case–control study including 180 non-competi-tive recreational male bodybuilders from August/2007 to March/2009. Ninety-five had a history of intramuscular AAS use (cases; G1) and 85 were non-users (controls; G2). They underwent a clinical evaluation and abdominal ultra- sound, and their blood levels of aminotransferases, creatine phosphokinase (CPK), lipids, glucose and insulin were measured. TAFLD criteria: history of AAS use 42 years; presence of hepatic steatosis on ultrasound and/or aminotransferase alterations with normal CPK levels; exclusion of ethanol intake Z20 g/day or use of other drugs; and exclusion of obesity, dyslipidae-mia, diabetes and other liver diseases. Homeostasis model assessment for insulin resistance Z3 was considered insulin resistant. Independent t-test, odds ratio (OR) and 95% confidence intervals (95% CI) were calculated. Results: All cases were asymptomatic. Clinical and laboratorial data were similar in G1 and G2 (P40.05). TAFLD criteria were observed in 12.6% of the G1 cases and 2.4% of controls had criteria compliant with non-alcoholic fatty liver related to metabolic conditions. OR was 6.0 (95% CI: 1.3–27.6). Conclusions: These results suggest that AAS could be a possible new risk factor for TAFLD. In this type of fatty liver disease, the individuals had a low body fat mass and they did not present insulin resistance

Topics: anabolic agents, drug use, non-alcoholic, fatty liver disease, steatosis, toxicant, associated fatty liver disease
Year: 2012
OAI identifier: oai:agregador.ibict.br.RI_UFBA:oai:192.168.11:11:ri/5470
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.rcaap.pt/detail.jsp... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.